Exceptional Response to Crizotinib With Subsequent Response to Cabozantinib in Metastatic, ROS1-GOPC Fusion–Mutated Breast Cancer

O’Neil, S. R., Weber, G. A., Deming, D. A., Burkard, M. E., Kenny, P. A., Richmond, C. S., & Parsons, B. M. (2023). Exceptional Response to Crizotinib With Subsequent Response to Cabozantinib in Metastatic, ROS1-GOPC Fusion–Mutated Breast Cancer. JCO Precision Oncology, (7). https://doi.org/10.1200/po.23.00174